FDA Oncology Update

Pluvicto FDA Approved for PSMA-Positive Metastatic Prostate Cancer

Opdualag, a Novel Immunotherapy Combination, FDA Approved for Advanced Melanoma

Carvykti Second BCMA-Directed CAR T-Cell Therapy FDA Approved for Multiple Myeloma

Keytruda Monotherapy FDA Approved for Endometrial Carcinoma with a Biomarker

Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer with BRCA Mutation

Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC

Kimmtrak, a Bispecific CD3 T-Cell Engager, First FDA-Approved Drug for Unresectable or Metastatic Uveal Melanoma

Orencia First Drug FDA Approved for the Prevention of Acute Graft-versus-Host Disease

Keytruda Now Approved for the Adjuvant Treatment of Stage IIB/IIC Melanoma

Rituximab plus Chemotherapy FDA Approved for Several Pediatric Hematologic Malignancies

1
2
3
4

Page 1 of 19
Results 1 - 10 of 181

Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.